Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationDifferent doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationThe blind men and the AML elephant: can we feel the progress?Stem Cell Modeling of Core Binding Factor Acute Myeloid LeukemiaDefining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceAn update of current treatments for adult acute myeloid leukemiaChildhood acute myeloid leukaemiaAntibody Drug Conjugates: Preclinical ConsiderationsProgress in acute myeloid leukemiaUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesWhy has demand for platelet components increased? A reviewAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.Interpreting outcome data in hematological malignancies: a paradigm for clinical studiesAddition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study.Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.Gemtuzumab ozogamicin: time to resurrect?Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisAcute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Acute myeloid leukemia: 2014 update on risk-stratification and management.Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemiaGemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicEarly versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemiaAutologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinAnti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
P2860
Q24186359-01C22F50-9B85-4153-8AA4-3EF296DF7782Q24186913-F8DFEE28-9654-438F-B18D-96DC0AA060B8Q24187751-A3C313C4-F808-48AA-8E05-727F29046134Q24198288-50D50C85-526D-4FE0-9BB7-8C84D3FC224CQ24198774-F14B3CAB-23C5-4864-8208-2C681FF2E709Q24198795-9262E2B2-AD1A-4B14-9166-73A27DDD6A9DQ24198832-03C93CB4-AD4F-4BCD-96ED-19B6D729CE8DQ26749614-889340F9-1C48-4ADA-9ACC-4218C4B78088Q26765858-12B2746C-E41C-4183-95F5-AC85D1B70122Q26772235-7D2C5A94-6EE7-47EA-8409-C6C69078B368Q26776393-CFDC6603-2C66-4988-832A-DF9BBAF69E1CQ26776396-47E46855-38AF-4C89-B50E-DB2C5595B072Q27005960-8AEF7080-1D33-4BFD-A518-7B432F16F11FQ27022321-51B11BE9-D5C9-44EB-99A2-C4EB1E6D169CQ27024006-4E83E987-5B3E-484A-A1A6-FEFF7F14116CQ28071384-EC084C77-1E71-44B9-AA3F-F20F5D8535BBQ28249969-E7C1BAEE-5995-44DD-83ED-AB828E26D2F0Q28484890-83038D69-B70B-467B-AFC3-C8C726EC027DQ30248355-893F7B38-4C8C-4F78-8ADB-D387E59BA3BCQ30658847-8029F205-00AD-4585-AAC0-21967008D0C5Q30835785-085417F4-CDC8-4878-8FE6-75EA0250B1CFQ33415057-683100B8-96F5-4A60-89B6-EC105B9BBC34Q33572303-07B353BA-0EDB-44B9-B046-7AFEB2D4FBCBQ33643108-5D74DB2E-BBDC-4468-AECD-4831CF84A810Q33832709-58036493-3D37-48D3-8499-12B7CC92E6F5Q33903030-6FAD493D-3904-4398-828A-CC4F62044529Q34172042-5D503D49-C947-4798-8B6A-FCAFC50E01C7Q34207336-2D2AB51D-82E4-4873-A99E-EF97B79F4472Q34300325-57C84E36-C98E-47AB-BA5C-2A948022713BQ34421932-43E48AA6-F457-4AD5-96A6-D458FAD53C9DQ34428556-A55A7347-1687-4801-B891-2017B53CFE4FQ34655572-35A2E897-F9AB-4F5B-A879-6749C225E463Q34663691-6D27D8F1-7687-46FC-B66E-998A09BB27EAQ34665691-D451EFD9-01AB-4722-A812-B55FA357AB5BQ34673820-A33FE742-C122-4D56-9CDC-00E906AA1D93Q34742630-779B59C1-2355-4C72-BBEB-55D04EF92A18Q34817365-89196434-E5D7-472D-8DAC-E53D6C3A38CBQ34937415-B2C6588C-BA9C-4BC1-8A8E-A0A0E49EFBEFQ35029920-9DD54448-4243-46AE-A81C-56694D543ECEQ35146288-1C919199-0C29-4C13-9873-DD86BC7CC81B
P2860
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Identification of patients wit ...... esults of the MRC AML15 trial.
@en
Identification of patients wit ...... esults of the MRC AML15 trial.
@nl
type
label
Identification of patients wit ...... esults of the MRC AML15 trial.
@en
Identification of patients wit ...... esults of the MRC AML15 trial.
@nl
prefLabel
Identification of patients wit ...... esults of the MRC AML15 trial.
@en
Identification of patients wit ...... esults of the MRC AML15 trial.
@nl
P2093
P356
P1476
Identification of patients wit ...... esults of the MRC AML15 trial.
@en
P2093
Alan K Burnett
Ann Hunter
Anthony H Goldstone
Donald Milligan
John A L Yin
Jonathan Kell
Keith Wheatley
Lars Kjeldsen
Nigel H Russell
P304
P356
10.1200/JCO.2010.31.4310
P407
P577
2010-12-20T00:00:00Z